Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
Abstract Introduction Drotrecogin alfa (activated; recombinant activated protein C) was shown to reduce 28-day all-cause mortality in patients with severe sepsis and to have an acceptable safety profile in 1690 patients studied in the F1K-MC-EVAD (PROWESS) trial. We analyzed all available data on th...
Zapisane w:
| Główni autorzy: | , , , , , |
|---|---|
| Format: | Revisão |
| Język: | angielski |
| Wydane: |
2003
|
| Dostęp online: | https://doi.org/10.1186/cc2167 https://ccforum.biomedcentral.com/counter/pdf/10.1186/cc2167 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|